Skip to main content

Advertisement

SpringerLink
Log in

Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: focus on special populations

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Abstract

Elderly or frail patients are often excluded from clinical trials. As a result, clinical outcome of these patients may differ from those obtained in trials. This situation may also hold true for patients who have severe concomitant diseases such as renal, hepatic, or cardiac dysfunction. Being aware of the wide range of clinical situations that a specialist may face is important to ensure that under any circumstances, the patient will receive the best treatment possible. The Spanish Oncology Genitourinary Group issued its first public statement on recommendations for the optimal management of advanced renal cell carcinoma (RCC). However, some issues remained unsolved. In this report, we discuss the current role of Medical Oncology in the treatment of patients with advanced RCC and review the management of special patient populations, such as elderly or patients with concomitant diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Weikert, S., Boeing, H., Pischon, T., et al. (2008). Blood pressure and risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition. American Journal of Epidemiology, 167, 438–446.

    Article  PubMed  Google Scholar 

  2. Lowrance, W. T., Thompson, R. H., Yee, D. S., et al. (2010). Obesity is associated with a higher risk of clear-cell renal cell carcinoma than with other histologies. BJU International, 105, 16–20.

    Article  PubMed  Google Scholar 

  3. Bajetta, E., Gevorgyan, A., & Mellstedt, H. (2007). National integration of European standards. Annals of Oncology, 18, 969–970.

    Article  CAS  PubMed  Google Scholar 

  4. Harding, M. J., Paul, J., Gillis, C. R., et al. (1993). Management of malignant teratoma: does referral to a specialist unit matter? Lancet, 341, 999–1002.

    Article  CAS  PubMed  Google Scholar 

  5. Hansen, H. H., Bajorin, D. F., Muss, H. B., et al. (2004). Recommendations for a Global Core Curriculum in Medical Oncology. Annals of Oncology, 15, 1603–1612.

    Article  CAS  PubMed  Google Scholar 

  6. Hutson, T. E., Figlin, R. A., Kuhn, J. G., et al. (2008). Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. The Oncologist, 13, 1084–1096.

    Article  CAS  PubMed  Google Scholar 

  7. Therasse, P., Le Cesne, A., Van Glabbeke, M., et al. (2005). RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma. European Journal of Cancer, 41, 1426–1430.

    Article  CAS  PubMed  Google Scholar 

  8. Gralow, J., Ozols, R. F., Bajorin, D. F., et al. (2008). Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening—a report from the American Society of Clinical Oncology. Journal of Clinical Oncology, 26, 313–325.

    Article  PubMed  Google Scholar 

  9. Gore, M. E., Szczylik, C., Porta, C., et al. (2009). Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. The Lancet Oncology, 10, 757–763.

    Article  CAS  PubMed  Google Scholar 

  10. Motzer, R. J., Hutson, T. E., Tomczak, P., et al. (2007). Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. The New England Journal of Medicine, 356, 115–124.

    Article  CAS  PubMed  Google Scholar 

  11. Eisen, T., Oudard, S., Szczylik, C., et al. (2008). Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. Journal of the National Cancer Institute, 100, 1454–1463.

    Article  CAS  PubMed  Google Scholar 

  12. Bajetta, E., Ravaud, A., Bracarda, S., et al. (2008). Efficacy and safety of first-line bevacizumab (BEV) plus interferon-α2a (IFN) in patients (pts) ≥65 years with metastatic renal cell carcinoma (mRCC). ASCO Meeting Abstracts 26:5095.

  13. Dutcher, J. P., Szczylik, C., Tannir, N., et al. (2007). Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN). ASCO Meeting Abstracts 25:5033.

    Google Scholar 

  14. Hutson, T. E., Calvo, E., Escudier, B. J., et al. (2010). Everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the RECORD-1 study. San Francisco: ASCO Genitourinary Cancers Symposium.

  15. Chen, M. H. (2009). Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue. Current Cardiology Reports, 11, 167–174.

    Article  CAS  PubMed  Google Scholar 

  16. FDA (2009). Bevacizumab (Avastin®)—full prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125085s0168lbl.pdf.

  17. Escudier, B. J., Bellmunt, J., Negrier, S., et al. (2009). Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology (Meeting Abstracts) 27:5020.

    Google Scholar 

  18. Escudier, B., Eisen, T., Stadler, W. M., et al. (2009). Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. Journal of Clinical Oncology, 27, 3312–3318.

    Article  CAS  PubMed  Google Scholar 

  19. Motzer, R. J., Hutson, T. E., Tomczak, P., et al. (2009). Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology, 27, 3584–3590.

    Article  CAS  PubMed  Google Scholar 

  20. Schmidinger, M., Zielinski, C. C., Vogl, U. M., et al. (2008). Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology, 26, 5204–5212.

    Article  PubMed  Google Scholar 

  21. Motzer, R. J., Escudier, B., Oudard, S., et al. (2008). Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet, 372, 449–456.

    Article  CAS  PubMed  Google Scholar 

  22. Hudes, G., Carducci, M., Tomczak, P., et al. (2007). Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. The New England Journal of Medicine, 356, 2271–2281.

    Article  CAS  PubMed  Google Scholar 

  23. Humphreys, B. D., Soiffer, R. J., & Magee, C. C. (2005). Renal failure associated with cancer and its treatment: an update. Journal of the American Society of Nephrology, 16, 151–161.

    Article  PubMed  Google Scholar 

  24. Gupta, S., Parsa, V., Heilbrun, L., et al. (2009). Safety and efficacy analysis of sunitinib (S), bevacizumab (B), and M-Tor inhibitors in metastatic renal cell cancer (mRCC) patients (pts) with renal insufficiency (RI). ASCO Meeting Abstracts 27:5108.

  25. Khosravan, R., Toh, M., Garrett, M., et al. (2010). Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function. Journal of Clinical Pharmacology, 50, 472–481.

    Article  CAS  PubMed  Google Scholar 

  26. Miller, A. A., Murry, D. J., Owzar, K., et al. (2009). Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. Journal of Clinical Oncology, 27, 1800–1805.

    Article  CAS  PubMed  Google Scholar 

  27. Maroto, R. P., & Villavicencio, H. (2008). Sorafenib: tolerance in patients on chronic hemodialysis. Oncology, 74, 245.

    Article  Google Scholar 

  28. Lunardi, G., Armirotti, A., Nicodemo, M., et al. (2009). Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: a case series. Clinical Therapeutics, 31, 1812–1819.

    Article  CAS  PubMed  Google Scholar 

  29. Bellmunt, J., Szczylik, C., Feingold, J., et al. (2008). Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Annals of Oncology, 19, 1387–1392.

    Article  CAS  PubMed  Google Scholar 

  30. Castroagudín, J. F., Molina, E., Romero, R., et al. (2009). Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction. Liver Transplantation, 15, 1792–1797.

    Article  PubMed  Google Scholar 

  31. Moro, J., Almenar, L., Martínez-Dolz, L., et al. (2007). mTOR inhibitors: do they help preserve renal function? Transplantation Proceedings, 39, 2135–2137.

    Article  CAS  PubMed  Google Scholar 

  32. Bello, C. L., Garrett, M., Smeraglia, J., et al. (2009). Pharmacokinetics (PK) of sunitinib malate (SU11248) in subjects with hepatic impairment. Annals of Oncology, 17, 148.

    Google Scholar 

  33. EMEA (2009). Temsirolimus (Torisel®)—summary of product characteristics. http://www.ema.europa.eu/humandocs/PDFs/EPAR/torisel/emea-combined-h799en.pdf.

  34. FDA (2007). Temsirolimus (Torisel®)—full prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022088lbl.pdf.

  35. Zekri, J., Ahmed, N., Coleman, R. E., et al. (2001). The skeletal metastatic complications of renal cell carcinoma. International Journal of Oncology, 19, 379–382.

    CAS  PubMed  Google Scholar 

  36. Polascik, T. J. (2009). Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases. Drug Design Development Therapy, 3, 27–40.

    CAS  Google Scholar 

  37. Lipton, A., Zheng, M., & Seaman, J. (2003). Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer, 98, 962–969.

    Article  CAS  PubMed  Google Scholar 

  38. Christodoulou, C., Pervena, A., Klouvas, G., et al. (2009). Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology, 76, 209–211.

    Article  CAS  PubMed  Google Scholar 

  39. Bukowski, R. M. (2009). Prognostic factors for survival in metastatic renal cell carcinoma: update 2008. Cancer, 115, 2273–2281.

    Article  CAS  PubMed  Google Scholar 

  40. Schackert, G., Price, J. E., Bucana, C. D., et al. (1989). Unique patterns of brain metastasis produced by different human carcinomas in athymic nude mice. International Journal of Cancer, 44, 892–897.

    Article  CAS  Google Scholar 

  41. Kim, L. S., Huang, S., Lu, W., et al. (2004). Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice. Clinical & Experimental Metastasis, 21, 107–118.

    Article  CAS  Google Scholar 

  42. Yano, S., Shinohara, H., Herbst, R. S., et al. (2000). Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Research, 60, 4959–4967.

    CAS  PubMed  Google Scholar 

  43. Massard, C., Zonierek, J., Gross-Goupil, M., et al. (2009). Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Annals of Oncology, 21, 1027–1031.

    Article  PubMed  Google Scholar 

  44. Walther, M. M., Patel, B., Choyke, P. L., et al. (1997). Hypercalcemia in patients with metastatic renal cell carcinoma: effect of nephrectomy and metabolic evaluation. Journal d'Urologie, 158, 733–739.

    Article  CAS  Google Scholar 

  45. Montie, J. E., Stewart, B. H., Straffon, R. A., et al. (1977). The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. Journal d'Urologie, 117, 272–275.

    CAS  Google Scholar 

  46. Marcus, S. G., Choyke, P. L., Reiter, R., et al. (1993). Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. Journal d'Urologie, 150, 463–466.

    CAS  Google Scholar 

  47. Flanigan, R. C., Salmon, S. E., Blumenstein, B. A., et al. (2001). Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. The New England Journal of Medicine, 345, 1655–1659.

    Article  CAS  PubMed  Google Scholar 

  48. Mickisch, G. H., Garin, A., van Poppel, H., et al. (2001). Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet, 358, 966–970.

    Article  CAS  PubMed  Google Scholar 

  49. Gatenby, R. A., Gawlinski, E. T., Tangen, C. M., et al. (2002). The possible role of postoperative azotemia in enhanced survival of patients with metastatic renal cancer after cytoreductive nephrectomy. Cancer Research, 62, 5218–5222.

    CAS  PubMed  Google Scholar 

  50. Escudier, B., Pluzanska, A., Koralewski, P., et al. (2007). Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet, 370, 2103–2111.

    Article  PubMed  Google Scholar 

  51. Szczylik, C., Porta, C., Bracarda, S., et al. (2008). Sunitinib in patients with or without prior nephrectomy (Nx) in an expanded access trial of metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology (Meeting Abstracts), 26, 5124.

    Google Scholar 

  52. Logan, T., McDermott, D. F., Dutcher, J. P., et al. (2008). Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poor-risk features. Journal of Clinical Oncology (Meeting Abstracts), 26, 5050.

    Google Scholar 

  53. Cho, D., Signoretti, S., Dabora, S., et al. (2007). Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clinical Genitourinary Cancer, 5, 379–385.

    Article  CAS  PubMed  Google Scholar 

  54. Rabets, J. C., Kaouk, J., Fergany, A., et al. (2004). Laparoscopic versus open cytoreductive nephrectomy for metastatic renal cell carcinoma. Urology, 64, 930–934.

    Article  PubMed  Google Scholar 

  55. Walther, M. M., Lyne, J. C., Libutti, S. K., et al. (1999). Laparoscopic cytoreductive nephrectomy as preparation for administration of systemic interleukin-2 in the treatment of metastatic renal cell carcinoma: a pilot study. Urology, 53, 496–501.

    Article  CAS  PubMed  Google Scholar 

  56. Schrader, A. J., Olbert, P. J., Hegele, A., et al. (2008). Metastatic non-clear cell renal cell carcinoma: current therapeutic options. BJU International, 101, 1343–1345.

    Article  CAS  PubMed  Google Scholar 

  57. Patard, J. J., Leray, E., Rioux-Leclercq, N., et al. (2005). Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. Journal of Clinical Oncology, 23, 2763–2771.

    Article  PubMed  Google Scholar 

  58. Schrader, A. J., Rauer-Bruening, S., Olbert, P. J., et al. (2009). Incidence and long-term prognosis of papillary renal cell carcinoma. Journal of Cancer Research and Clinical Oncology, 135, 799–805.

    Article  CAS  PubMed  Google Scholar 

  59. Störkel, S., Eble, J. N., Adlakha, K., et al. (1997). Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer, 80, 987–989.

    Article  PubMed  Google Scholar 

  60. Steiner, T., Roigas, J., Kirchner, H., et al. (2006). Clinical course of patients with metastatic papillary renal cell carcinoma. ASCO Meeting Abstracts 24:14591.

  61. Dutcher, J. P., de Souza, P., McDermott, D., et al. (2009). Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Medical Oncology, 26, 202–209.

    Article  CAS  PubMed  Google Scholar 

  62. Choueiri, T. K., Plantade, A., Elson, P., et al. (2008). Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. Journal of Clinical Oncology, 26, 127–131.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors acknowledge the support of Novartis Farmacéutica, which facilitated the necessary meetings to evaluate and discuss all the data presented in this review, and Dr. Beatriz Gil-Alberdi from HealthCo SL (Madrid, Spain) for her assistance in the preparation of this manuscript.

Conflict of Interest

E. Calvo has received consulting fees from Roche, Pfizer, Novartis. He has received honoraria from Roche, Pfizer, Novartis. He has received research funding from Roche, Pfizer, Novartis. P. Maroto has received consulting fees from Wyeth, Pfizer. He has received honoraria from Wyeth, Roche, Pfizer, Bayer. X. Garcia del Muro has no conflict of interest. M. A. Climent has received consulting fees from Bayer, GSK, Pfizer, Novartis. He has received honoraria from Wyeth. J. L. González-Larriba has no conflict of interest. E. Esteban has no conflict of interest. R. Lopez has received consulting fees from Novartis, Roche, GSK. He has received research funding from Novartis. L. Paz-Ares has honoraria from Pfizer, Novartis. J. Bellmunt has received consulting fees from Bayer, Roche, Pfizer, Novartis. D. Castellano has no conflict of interest.

Author information

Authors and Affiliations

  1. Hospital de Madrid-CIOCC, Madrid, Spain

    Emiliano Calvo

  2. Hospital de la Santa Creu i San Pau, Barcelona, Spain

    Pablo Maroto

  3. Institut Català d’Oncologia, Barcelona, Spain

    Xavier García del Muro

  4. Instituto Valenciano de Oncología, Valencia, Spain

    Miguel Ángel Climent

  5. Hospital Clínico San Carlos, Madrid, Spain

    José Luis González-Larriba

  6. Hospital Universitario Central de Asturias, Oviedo, Spain

    Emilio Esteban

  7. Complexo Hospitalario Universitario de Santiago, A Coruña, Spain

    Rafael López

  8. Hospital Virgen del Rocío, Sevilla, Spain

    Luis Paz-Ares

  9. Hospital del Mar, Barcelona, Spain

    Joaquim Bellmunt

  10. Medical Oncology Service, Hospital Universitario 12 de Octubre, Avda. De Córdoba, s/n, 28041, Madrid, Spain

    Daniel Castellano

Authors
  1. Emiliano Calvo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pablo Maroto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xavier García del Muro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Miguel Ángel Climent
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. José Luis González-Larriba
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Emilio Esteban
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rafael López
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Luis Paz-Ares
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Joaquim Bellmunt
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Daniel Castellano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel Castellano.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Calvo, E., Maroto, P., del Muro, X.G. et al. Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: focus on special populations. Cancer Metastasis Rev 29 (Suppl 1), 11–20 (2010). https://doi.org/10.1007/s10555-010-9232-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10555-010-9232-5

Keywords

Search

Navigation